A Department of Defense (DoD)-funded Phase I/II clinical study on TapImmune's HER2/neu-targeted T-cell vaccine for women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS)
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2018
At a glance
- Drugs TPIV 110 (Primary)
- Indications Carcinoma; Early breast cancer
- Focus Therapeutic Use
- 17 Oct 2018 According to a Marker Therapeutics Inc, the TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc.
- 31 Aug 2017 According to a TapImmune media release, the company plans to initiate a Phase 1b/2a clinical trial of TPIV 110 for treating women with HER2/neu+ breast cancer once an amended investigational new drug application (IND) is completed by year-end 2017 and upon FDA acceptance of the amended IND.
- 17 Mar 2017 New trial record